Abstract
18F-FDG PET studies were shown to be quite sensitive to inflammation as well to a variety of benign diseases that induce focal increase in metabolism [1–3]. While in most countries PET imaging of these diseases are not reimbursed, it remains a potential alternative imaging modality for selected cases. FDG-PET remains a sensitive diagnostic modality for detection of infectious diseases and exploring sources of fever of unknown origin. In this chapter several diseases are presented, but also examples of identification and characterization of vascular plaques [4]. While 18F-FDG is being reported as a potential marker of plaque inflammatory process and therefore may help identify unstable plaques and be a predictor of cardiovascular events, alternative PET tracers are also being evaluated for better characterization of vascular plaques [4–6]. Another application domain of PET and therefore could potentially benefit from hybrid PET-MR is the assessment of neurodegenerative diseases and differentiation of diagnostic classification based on anatomical distribution of brain metabolic activity.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
- Cardiac Sarcoidosis
- Posterior Cortical Atrophy
- Neurodegenerative Dementia
- Vascular Plaque
- Brain Metabolic Activity
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Benign, Degenerative and Inflammatory Diseases
18F-FDG PET studies were shown to be quite sensitive to inflammation as well to a variety of benign diseases that induce focal increase in metabolism [1–3]. While in most countries PET imaging of these diseases are not reimbursed, it remains a potential alternative imaging modality for selected cases. FDG-PET remains a sensitive diagnostic modality for detection of infectious diseases and exploring sources of fever of unknown origin. In this chapter several diseases are presented, but also examples of identification and characterization of vascular plaques [4]. While 18F-FDG is being reported as a potential marker of plaque inflammatory process and therefore may help identify unstable plaques and be a predictor of cardiovascular events, alternative PET tracers are also being evaluated for better characterization of vascular plaques [4–6].
Another application domain of PET and therefore could potentially benefit from hybrid PET/MR is the assessment of neurodegenerative diseases and differentiation of diagnostic classification based on anatomical distribution of brain metabolic activity. Many studies reported the added value of 18F-FDG in dementia in complementarity to MRI findings [7–9]. Future development of new specific tracers will bring additional potential applications of for PET imaging in combination with MRI [10, 11].
Atherosclerotic Plaque at Carotid Bifurcation
Clinical History
Fifty-nine-year-old man with history of an intermittent weakness of the left hand. An ultrasound examination of the right internal carotid artery shows a slight stenosis.
Imaging Technique
PET/MR image acquired 140 min after iv injection of 421 MBq 18F-FDG.
1 bed position × 15 min together with axial TOF, T2w TSE, T1w TSE native and post injection of 17 ml of Gd-DTPA MR contrast agent (CA). Head/neck and dedicated phased-array carotid coil.
Findings
A mild stenosis of right carotid artery slightly above bifurcation is observed. Axial high resolution TSE images show morphology of outward plaque remodeling. Different MR contrast weightings allow distinguishing plaque constituents. Faint uptake of 18F-FDG tracer at plaque location indicates possible inflammatory status of the plaque.
Teaching Points
In atherosclerosis characterization of the so-called “vulnerable” plaque at risk for disruption is critical to predict adverse events. PET/MR allows for identification of atherosclerotic plaque morphology and functional status.
Stress Fracture
Clinical History
Fifty-nine-year-old female patient with osteosynthetic supply of the right ankle after a complex fracture 1.5 years ago. The patients suffers from increasing pain of the right foot developing over the last few months. A prior X-ray was negative.
Imaging Technique
PET/MR of the right foot acquired 126 min after iv injection 326 MBq 18F-Flouride, 78 kg.
1 bed × 10 min together with sagittal T1w TSE/ PDw fs, axial T1w TSE/ PDw fs and coronal T2w TSE. Flex coil.
Findings
Bone marrow edema and high osteoblastic activity in PET indicate an active process in the cuboid bone. Only mild edema and minor uptake combined with a clear stress fracture line are signs of a more chronic process in the calcaneus.
Teaching Points
18F-Flouride PET and MRI can provide complementary information in patients with chronic foot pain. The combination of T1w TSE outlining a potential fracture line and the extent of osteoblastic activity is helpful in the differentiation between an active and chronic process.
Multicystic Disease
Clinical History
65 y.o. patient with polycystic disease and status post renal transplant due to renal insufficiency. Diagnostic staging for possible lymphoma.
Imaging Technique
PET: Whole-body PET acquired 60 min after injection of 369 MBq of 18F-FDG, 57 kg/157 cm patient, with 5.2 mmol/L of fasting glycemia.
MRI: Whole body atMR (T1 weighted), supine position. 3D TSE T2 weighted whole-body MRI.
Findings
PET/MR images confirmed the diffuse polycystic disease with only mild focal uptake of some retro-peritoneal and para-aortic lymph nodes with strong evidence of any malignant disease.
Teaching Points
In patients with renal insufficiency and complex clinical history, high resolution MR of hybrid PET/MR can replace PET/CT studies for whole-body staging.
Kaposi Sarcoma
Clinical History
61 y.o. patient with known Kaposi sarcoma in an endemic African form associated with HHV8 virus often associated with HIV positive subjects.
Imaging Technique
PET: Whole-body PET acquired 60 min after injection of 377 MBq 18F-FDG, 83 kg/169 cm patient.
MRI: Whole body atMR (T1 weighted), supine position. 3D TSE T2 weighted whole-body MRI.
Findings
PET/MR images multiple subcutaneous lesions with high FDG uptake corresponding to the Kaposi sarcoma lesions, with only one distant hypermetabolic lesion of the left thigh.
Teaching Points
In soft-tissue lesions, MRI can provide a wealth of different imaging sequences for better characterization and localization of focal hypermetabolic lesions seen on PET.
Maffucci Syndrome
Clinical History
29 y.o. patient with a Maffucci syndrome (a rare non-hereditary syndrome characterized by the presence of multiple enchondromas associated with multiple hemangiomas) who underwent several surgical interventions for bone lesions of the lower limbs. Study requested for assessment of a rapidly growing lesion of the left shoulder.
Imaging Technique
PET: Whole-body PET acquired 60 min after injection of 370 MBq of 18F-FDG.
MRI: Whole body atMR (T1 weighted), supine position. 3D TSE T2 weighted whole-body MRI.
Findings
PET/MR images confirmed the wide spread of endochondroma lesions across the whole body with mild to moderate FDG uptake. A growing lesion of the left shoulder showed moderate homogeneous FDG uptake with no evidence of malignant transformation.
Teaching Points
Multi-parametric criteria from MRI tissue characteristics and patterns of FDG uptake can help differentiate benign from malignant lesions in soft tissue tumors.
Giant Cell Vasculitis
Clinical History
Seventy-two-year-old patient presenting with elevated CRP and chest pain.
Imaging Technique
PET/MR images of the whole body were acquired 108 min after iv injection 420 MBq18F-FDG.
Coronal T2w STIR MRI, GRE MRI before and after application of CM.
Findings
Increased glucose metabolism in the vessel wall of the descending thoracic aorta was found to correlate with hyperintense changes seen in T2w MRI.
Teaching Points
FDG-PET detects pathological tracer uptake in vascular wall which confirms active vasculitis. MRI helps to localize vascular uptake and allows correlation with morphological changes of the vessel wall.
Cardiac Sarcoidosis
Clinical History
A 30-year-old male patient was referred to our institution because of suspected cardiac involvement of a newly diagnosed sarcoidosis. Coronary angiography excluded coronary artery disease and showed a severely reduced left ventricular function. A CT of the chest demonstrated bihilar lymphadenopathy. Subsequently, the patient was transferred to our institution to confirm cardiac involvement of the sarcoidosis by PET/MR.
Imaging Technique
To suppress physiological glucose uptake of the myocardium the patient was put on a low-carbohydrate diet for 1 day and had to fast 12 h prior to the scan. PET/MR images were acquired 64 min after iv injection of 238 MBq 18F-FDG. Furthermore, myocardial perfusion was assessed at resting conditions by slow bolus iv injection over 30 s of 219 MBq 13N-ammonia. MR: T1 VIBE Dixon for attenuation correction, True-FISP CINE (wall motion), T1 IR 15 min. 40 ml of Gd-DTPA were injected.
Findings
Bihilar lymphadenopathy with increased FDG uptake in the lymph nodes confirms the diagnosis of sarcoidosis. Areas in the left ventricle with increased FDG uptake and reduced perfusion indicate active inflammation and reveal cardiac involvement of the sarcoidosis. Also, a severely reduced left ventricular ejection fraction with severe hypokinesis of the lateral wall demonstrates dilated cardiomyopathy (DCM) as a consequence of cardiac sarcoidosis. Furthermore, areas demonstrating late gadolinium enhancement (LGE) indicate myocardial infiltration and scarring.
Teaching Points
Late gadolinium enhancement appears predominantly in epicardial regions of the myocardium when cardiac involvement of sarcoidosis is present and only rarely spreads to the endocardium. Areas of LGE represent fibrotic changes as a consequence of fibroganulomatous replacement of the myocardium.
Different patterns of perfusion and glucose metabolism in PET in the case of cardiac involvement of sarcoidosis are known. Normal perfusion and active inflammation represent an early stage of the disease, while reduced perfusion and active inflammation indicates an advanced stage. Finally, reduced or absent perfusion and no inflammation indicates end-stage cardiac sarcoidosis.
The integrated information of PET and MR allow exact assessment of the stage and inflammatory state of the disease and therapy monitoring.
Frontotemporal Dementia (FTD)
Clinical History
Forty-nine-year-old patient with behavioural deficits and increasing memory loss. Study requested for differential diagnosis of possible neurodegenerative dementia.
Imaging Technique
PET measurement started 62 min after injection of 151 MBq [18F]FDG. Simultaneous acquisition of MRI sequences (Dixon and 3D T1).
Findings
Transaxial PET image shows a pattern of reduced bihemispheric [18F]FDG tracer uptake in the frontal lobe and relative sparing of posterior brain regions, especially the percutaneous. The fusion images (Fig. 12.32) [18F]FDG-PET/T1w MRI in 3 projections shows that the regions of reduced [18F]FDG tracer uptake correspond to the regions with most pronounced brain atrophy (frontal lobe). Finally, coronal T1w MRI (below) shows no signs of hippocampal atrophy.
Teaching Points
The combination of functional [18F]FDG-PET and structural MR information leads to the most likely diagnosis of frontotemporal dementia (FTD). The main differential diagnosis behavioural atypical variant of Alzheimer’s Disease (AD) is unlikely due to normal metabolism in the precuneus/posterior cingulate region and due to lack of hippocampal atrophy.
Alzheimer’s Disease (AD)
Clinical History
Seventy-three-year-old male subject with slowly progressing memory deficits since 4 years. Study requested for differential diagnosis of neurodegenerative dementia.
Imaging Technique
[18F]FDG-PET measurement started 57 min after injection of 155 MBq [18F]FDG. Simultaneous acquisition of MRI sequences (Dixon, 3D T1 and coronal T2).
Findings
Parietal hypometabolism in [18F]FDG-PET images is indicative of AD. MRI data including volumetric T1w sequence showing severe global brain atrophy as well as hippocampal atrophy in T2 w coronal sequence confirms the diagnosis.
Teaching Points
The combination of functional and structural information strengthens the diagnosis of Alzheimer’s Disease.
Posterior Cortical Atrophy
Clinical History
Sixty-eight-year-old patient with predominant visuo-spatial deficits as well as cognitive decline. Neurodegenerative dementia? DD? Structural abnormality?
Imaging Technique
Two separate studies were performed with different tracers: F18-FDG and C11-PIB. FDG-PET measurement started 60 min after injection of 151 MBq F18-FDG. PiB-PET measurement started 41 min after injection of 371 MBq C11-PiB. Simultaneous acquisition of MRI sequences (Dixon, 3D T1).
Findings
Transaxial FDG-PET images (Fig. 12.37) show a asymmetrically reduced parietal and temporo-occipital FDG tracer uptake predominantly in the right occipital lobe extending from the cortex into the white matter including a photopenic lesion without any FDG uptake. The fusion images FDG-PET/T1w MRI in 3 projections (Fig. 12.38) show that the photopenic lesion without any FDG tracer uptake corresponds to an irregular dorsal extension of the right ventricle. Additionally, reduced bilateral occipital FDG tracer uptake and the respective occipital cortical atrophy is seen. PiB-PET image (Fig. 12.39) shows diffusely increased PiB tracer uptake in bilateral cortical regions peaking in the precuneus as well as increased subcortical PiB tracer uptake in bilateral striatum.
Teaching Points
Although information provided by PET alone would already favour diagnosis of AD, structural MR information helps in further differentiating the etiology by clarifying the asymmetrical hypometabolic/photopenic lesion in the right occipital lobe and in detecting the distinct bilateral occipital cortical atrophy, suggesting posterior cortical atrophy as final diagnosis.
References
Balink H, Collins J, Bruyn GA, Bruyn G, Gemmel F (2009) F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med 34:862–868
Basu S, Kumar R, Alavi A (2010) PET and PET/CT imaging in infection and inflammation: its critical role in assessing complications related to therapeutic interventions in patients with cancer. Indian J Cancer 47:371–379
Yokota S, Kikuchi M, Nozawa T, Kizawa T, Kanetaka T, Kadota K, Miyamae T, Mori M (2012) Febrile responses in patients with pediatric rheumatic diseases. Nihon Rinsho Meneki Gakkai Kaishi 35:511–519
Temma T, Saji H (2012) Radiolabelled probes for imaging of atherosclerotic plaques. Am J Nucl Med Mol Imaging 2:432–447
Dweck MR, Chow MWL, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJR, Boon NA, Rudd JHF, Newby DE (2012) Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol 59:1539–1548
Hermann S, Starsichova A, Waschkau B, Kuhlmann M, Wenning C, Schober O, Schäfers M (2012) Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability? J Nucl Cardiol 19:609–617
Arnaldi D, Morbelli S, Morrone E, Campus C, Nobili F (2012) Cognitive impairment in degenerative parkinsonisms: role of radionuclide brain imaging. Q J Nucl Med Mol Imaging 56:55–67
de Souza LC, Lehéricy S, Dubois B, Stella F, Sarazin M (2012) Neuroimaging in dementias. Curr Opin Psychiatry 25:473–479
Lopez OL, McDade E, Riverol M, Becker JT (2011) Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol 24:532–541
Heiss W-D, Zimmermann-Meinzingen S (2012) PET imaging in the differential diagnosis of vascular dementia. J Neurol Sci 322:268–273
Lopez OL, McDade E, Riverol M, Becker JT (2011) Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol 24:532–541
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Beer, A.J. et al. (2013). Benign, Degenerative and Inflammatory Diseases. In: Ratib, O., Schwaiger, M., Beyer, T. (eds) Atlas of PET/MR Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-31292-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-31292-2_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-31291-5
Online ISBN: 978-3-642-31292-2
eBook Packages: MedicineMedicine (R0)